Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803824 | 0.78 | RECQL (0.42) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21258644 | 0.77 | KMT2A (0.45) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL16794682 | 0.77 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20697279 | 0.76 | MAPT (0.40) | KMT2AALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL21227487 | 0.72 | KMT2A (0.41) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL21227512 | 0.72 | KMT2A (0.41) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL15132784 | 0.71 | KMT2A (0.48) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL13120869 | 0.69 | RECQL (0.48) | KMT2AALDH1A1SMN1; SMN2RECQLL3MBTL1 | |
| SCHEMBL15803826 | 0.68 | RECQL (0.50) | KMT2AALDH1A1SMN1; SMN2RECQLL3MBTL1 | |
| SCHEMBL9101081 | 0.67 | KMT2A (0.43) | KMT2AMEN1ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.